<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673124</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-3026</org_study_id>
    <nct_id>NCT03673124</nct_id>
  </id_info>
  <brief_title>Ribociclib and Letrozole Treatment in Ovarian Cancer</brief_title>
  <official_title>A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the response to treatment with Ribociclib and Letrozole in patients with&#xD;
      low grade serous cancer of the ovary, fallopian tube or peritoneum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ribociclib (formerly LEE011) is an orally bioavailable, highly selective small molecule&#xD;
      inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Ribociclib has been approved by the&#xD;
      United States Food and Drug Administration (U.S. FDA) and the European Commission as an&#xD;
      initial endocrine-based therapy for the treatment of postmenopausal women with hormone&#xD;
      receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or&#xD;
      metastatic breast cancer in combination with an aromatase inhibitor based on a randomized,&#xD;
      double-blind, placebo-controlled, international clinical trial (MONALEESA-2). Additional&#xD;
      marketing authorizations are under review by health authorities. Additional phase III&#xD;
      clinical trials for the treatment of hormone receptor positive (HR+) breast cancer patients,&#xD;
      as well as several other phase I or II clinical studies are being conducted.&#xD;
&#xD;
      Letrozole is a highly potent, orally active non-steroidal competitive inhibitor of the&#xD;
      aromatase enzyme system. It effectively inhibits the conversion of androgens to estrogens&#xD;
      both in vitro and in vivo. It is indicated both as first-line treatment of postmenopausal&#xD;
      women with hormone receptor positive or hormone receptor unknown locally advanced or&#xD;
      metastatic breast cancer as well as for the treatment of advanced breast cancer in&#xD;
      postmenopausal women with disease progression following antiestrogen therapy.&#xD;
&#xD;
      Based on encouraging results in women with advanced hormone-receptor-positive breast cancer,&#xD;
      a clinical trial for women with recurrent low-grade serous carcinoma is warranted.&#xD;
      Furthermore, such a trial would have great appeal to women with recurrent low-grade serous&#xD;
      carcinoma, a cohort with limited therapeutic options. Although low-grade serous carcinoma is&#xD;
      a rather uncommon histologic subtype, prolonged overall survival results in a relatively high&#xD;
      prevalence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>From date of protocol entry to date of first documented response assessed up to 5 years</time_frame>
    <description>Determine the response rate of patients receiving the combination of Ribociclib and Letrozole</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit (CR, PR, SD) rate</measure>
    <time_frame>From date of protocol entry to first documented response assessed up to 5 years</time_frame>
    <description>Determine the clinical benefit (CR, PR, and SD) rate of patients receiving the combination of letrozole + Ribociclib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity assessment (nature, frequency, and maximum degree of toxicity)</measure>
    <time_frame>every 4 weeks assessed up to 5 years</time_frame>
    <description>determine the nature, frequency, and maximum degree of toxicity associated with this combination using CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of protocol entry to date of first documented progression or death assessed up to 5 years</time_frame>
    <description>determine the progression-free survival of women receiving the combination of letrozole + Ribociclib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of protocol entry to date of first documented progression or death assessed up to 5 years</time_frame>
    <description>determine the overall survival of women receiving the combination of letrozole + Ribociclib.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ER expression</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>determine the expression of estrogen receptor (ER) and correlation with response and clinical benefit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mutation analysis of genomic signatures</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>determine genomic signatures associated with response and clinical benefit of the combination of letrozole + Ribociclib</description>
  </other_outcome>
  <other_outcome>
    <measure>PR expression</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>determine the expression of progesterone receptor (PR) and correlation with response and clinical benefit.</description>
  </other_outcome>
  <other_outcome>
    <measure>ki-67 expression</measure>
    <time_frame>At time of primary and secondary outcome analysis up to 5 years</time_frame>
    <description>determine the expression of proliferative index (ki-67) and correlation with response and clinical benefit.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Low Grade Serous Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ribociclib and letrozole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ribociclib 600mg oral daily for 3 weeks then 1 week off plus Letrozole 2.5 mg oral daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>600 mg by mouth daily for 21 days followed by 7 days off treatment</description>
    <arm_group_label>Ribociclib and letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>2.5 mg by mouth daily</description>
    <arm_group_label>Ribociclib and letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients eligible for inclusion in this study must meet all of the following criteria:&#xD;
&#xD;
          1. Patient has signed the Informed Consent (ICF) prior to any screening procedures being&#xD;
             performed and is able to comply with protocol requirements.&#xD;
&#xD;
          2. Age &gt; 18 years at time of study entry.&#xD;
&#xD;
          3. Willingness and ability to comply with study and follow-up procedures.&#xD;
&#xD;
          4. Histological confirmation of diagnosis of low-grade serous carcinoma of ovary,&#xD;
             fallopian tube or peritoneum; Original diagnosis of de novo low-grade serous carcinoma&#xD;
             or Original diagnosis of serous borderline tumor with subsequent diagnosis of&#xD;
             low-grade serous carcinoma.&#xD;
&#xD;
             â€¢ In order to prevent inclusion of patients with high-grade serous carcinoma,&#xD;
             diagnosis of low-grade serous carcinoma will be verified as part of screening review&#xD;
             by a gynecologic pathologist. Tissue for confirmation can be from primary tumor or&#xD;
             recurrence.&#xD;
&#xD;
          5. Patient must have recurrent, measurable disease by RECIST v1.1.&#xD;
&#xD;
          6. There are no restrictions on number of prior therapies.&#xD;
&#xD;
          7. Patient cannot have previously received a prior cyclin dependent kinase inhibitor&#xD;
             (CDKi). Patients who were treated with letrozole or another aromatase inhibitor for&#xD;
             other indications must have not taken the drug for 6 months prior to initiating&#xD;
             letrozole for this trial and may not have progressed on treatment.&#xD;
&#xD;
          8. Patients must not have remaining ovarian function to be included. In women who have at&#xD;
             least one retained ovary, menopause must be confirmed with laboratory confirmation.&#xD;
             Women who have ovarian function are eligible but must be placed on hormonal&#xD;
             suppression. Menopause must be confirmed with laboratory confirmation, to include an&#xD;
             estradiol level as this is assessed within 8 weeks of patient having been on&#xD;
             tamoxifen.&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2&#xD;
&#xD;
         10. Resolution of all acute toxic effects of prior therapy or surgical procedures to&#xD;
             National Cancer Institute (NCI) CTCAE Grade â‰¤ 1. Patients with grade 1 taxane-induced&#xD;
             neuropathy, any grade alopecia, amenorrhea, or other toxicities not considered a&#xD;
             safety risk for the patient as per investigator's discretion are eligible. 1. Patient&#xD;
             has adequate bone marrow and organ function as defined by the following laboratory&#xD;
             values at screening:&#xD;
&#xD;
               -  Absolute neutrophil count â‰¥1.5 Ã— 109/L&#xD;
&#xD;
               -  Platelets â‰¥100 Ã— 109/L&#xD;
&#xD;
               -  Hemoglobin â‰¥9.0 g/dL&#xD;
&#xD;
               -  Potassium, total calcium (corrected for serum albumin), magnesium, sodium and&#xD;
                  phosphorus within normal limits for the institution or corrected to within normal&#xD;
                  limits with supplements before first dose of study medication&#xD;
&#xD;
               -  INR â‰¤1.5 (unless patient is receiving permitted anticoagulants and the INR is&#xD;
                  within the therapeutic range of intended use for that anticoagulant within 7 days&#xD;
                  prior to the first dose of study drug). Serum creatinine &lt;1.5 mg/dL or creatinine&#xD;
                  clearance â‰¥50 mL/min&#xD;
&#xD;
               -  In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate&#xD;
                  aminotransferase (AST) &lt;2.5 x ULN. If the patient has liver metastases, ALT and&#xD;
                  AST &lt;5 x ULN&#xD;
&#xD;
               -  Total bilirubin &lt; ULN; or total bilirubin â‰¤3.0 x ULN or direct bilirubin â‰¤1.5 x&#xD;
                  ULN in patients with well-documented Gilbert's Syndrome.&#xD;
&#xD;
        12. Patient with available standard 12-lead ECG with the following parameters at screening:&#xD;
&#xD;
          -  QTcF interval at screening &lt;450msec (using Fridericia's correction)&#xD;
&#xD;
          -  Resting heart rate 50-90bpm 13. Must be able to swallow ribociclib and letrozole&#xD;
             capsules/tablets. 14. Patients receiving tamoxifen or toremifine must have washout&#xD;
             period of 5 half-lives prior to randomization.&#xD;
&#xD;
        Patients eligible for this study must not meet any of the following criteria:&#xD;
&#xD;
          1. Patient has a known hypersensitivity to any of the excipients of ribociclib or&#xD;
             letrozole.&#xD;
&#xD;
          2. Patient has a concurrent malignancy or malignancy within 3 years prior to starting&#xD;
             study drug, with the exception of adequately treated, basal or squamous cell&#xD;
             carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.&#xD;
             Patients with known brain metastases are excluded.&#xD;
&#xD;
          3. Patients with central nervous system (CNS) involvement unless they meet ALL of the&#xD;
             following criteria:&#xD;
&#xD;
               -  At least 4 weeks from prior therapy completion (including radiation and/or&#xD;
                  surgery) to starting the study treatment&#xD;
&#xD;
               -  Clinically stable CNS tumor at the time of screening and not receiving steroids&#xD;
                  and/or enzyme inducing anti-epileptic medications for brain metastases.&#xD;
&#xD;
          4. Patient has impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of the study drugs (e.g., ulcerative diseases,&#xD;
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel&#xD;
             resection).&#xD;
&#xD;
          5. Patient has a known history of HIV infection (testing not mandatory).&#xD;
&#xD;
          6. Patient has any other concurrent severe and/or uncontrolled medical condition that&#xD;
             would, in the investigator's judgment, cause unacceptable safety risks, contraindicate&#xD;
             patient participation in the clinical study or compromise compliance with the protocol&#xD;
             (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled&#xD;
             fungal, bacterial or viral infections, etc.).&#xD;
&#xD;
          7. Clinically significant, uncontrolled heart disease and/or cardiac repolarization&#xD;
             abnormalities, including any of the following:&#xD;
&#xD;
               -  History of acute coronary syndromes (including myocardial infarction, unstable&#xD;
                  angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or&#xD;
                  symptomatic pericarditis within 6 months prior to screening&#xD;
&#xD;
               -  History of documented congestive heart failure (New York Heart Association&#xD;
                  functional classification III-IV)&#xD;
&#xD;
               -  Documented cardiomyopathy&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction (LVEF) &lt;50% as determined by Multiple Gated&#xD;
                  acquisition (MUGA) scan or echocardiogram (ECHO)&#xD;
&#xD;
               -  Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia),&#xD;
                  complete left bundle branch block, high-grade AV block (e.g. bifascicular block,&#xD;
                  Mobitz type II and third-degree AV block)&#xD;
&#xD;
               -  Long QT syndrome or family history of idiopathic sudden death or congenital long&#xD;
                  QT syndrome, or any of the following:&#xD;
&#xD;
                    -  Risk factors for Torsades de Pointe (TdP) including uncorrected&#xD;
                       hypocalcemia, hypokalemia or hypomagnesemia, history of cardiac failure, or&#xD;
                       history of clinically significant/symptomatic bradycardia.&#xD;
&#xD;
                    -  Concomitant use of medication(s) with a known risk to prolong the QT&#xD;
                       interval and/or known to cause Torsades de Pointe that cannot be&#xD;
                       discontinued (within 5 half-lives or 7 days prior to starting study drug) or&#xD;
                       replaced by safe alternative medication&#xD;
&#xD;
                    -  Inability to determine the QT interval on screening (QTcF, using&#xD;
                       Fridericia's correction)&#xD;
&#xD;
                    -  Systolic blood pressure (SBP) &gt;160 mmHg or &lt;90 mmHg at screening&#xD;
&#xD;
          8. Patient is currently receiving any of the following medications and cannot be&#xD;
             discontinued 7 days prior to starting study drug (see Table 1 for details):&#xD;
&#xD;
               -  Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit&#xD;
                  hybrids, pummelos, star-fruit, and Seville oranges&#xD;
&#xD;
               -  That have a narrow therapeutic window and are predominantly metabolized through&#xD;
                  CYP3A4/5&#xD;
&#xD;
               -  Herbal preparations/medications, dietary supplements.&#xD;
&#xD;
          9. Participation in other studies involving investigational drug(s) within 30 days prior&#xD;
             to randomization or within 5 half-lives of the investigational product (whichever is&#xD;
             longer) or participation in any other type of medical research judged not to be&#xD;
             scientifically or medically compatible with this study. If the patient is enrolled or&#xD;
             planned to be enrolled in another study that does not involve an investigational drug,&#xD;
             the agreement of Novartis study medical lead is required to establish eligibility.&#xD;
&#xD;
         10. Patient is currently receiving warfarin or other coumadin-derived anticoagulant for&#xD;
             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight&#xD;
             heparin (LMWH) or fondaparinux is allowed. Direct-Acting Oral Anticoagulants (DOACS)&#xD;
             are permitted.&#xD;
&#xD;
         11. Patient is currently receiving or has received systemic corticosteroids â‰¤2 weeks prior&#xD;
             to starting study drug, or who have not fully recovered from side effects of such&#xD;
             treatment. The following uses of corticosteroids are permitted: a short duration (,5&#xD;
             days) of systemic corticosteriods; any durations of topical applications (e.g., for&#xD;
             rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local&#xD;
             injections (e.g., intra-articular)&#xD;
&#xD;
         12. Patient who has received radiotherapy â‰¤4 weeks or limited field radiation for&#xD;
             palliation â‰¤2 weeks prior to starting study drug, and who has not recovered to grade 1&#xD;
             or better from related side effects of such therapy (exceptions include alopecia)&#xD;
             and/or in whom â‰¥25% of the bone marrow (Ellis, 1961) was irradiated.&#xD;
&#xD;
         13. Patient has had major surgery within 14 days prior to starting study drug or has not&#xD;
             recovered from major side effects (tumor biopsy is not considered as major surgery).&#xD;
&#xD;
         14. Patient with a Child-Pugh score B or C.&#xD;
&#xD;
         15. Patients who are pregnant or breastfeeding.&#xD;
&#xD;
         16. Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using highly effective methods of contraception&#xD;
             throughout the study and for 3 weeks after study drug discontinuation. Highly&#xD;
             effective contraception methods include:&#xD;
&#xD;
               -  Total abstinence when this is in line with the preferred and usual lifestyle of&#xD;
                  the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception&#xD;
&#xD;
               -  Female sterilization (have had surgical bilateral oophorectomy with or without&#xD;
                  hysterectomy), total hysterectomy, or tubal ligation at least six weeks before&#xD;
                  taking study treatment. In case of oophorectomy alone, only when the reproductive&#xD;
                  status of the woman has been confirmed by follow up hormone level assessment&#xD;
&#xD;
             Women are considered post-menopausal and not of child bearing potential if they have&#xD;
             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile&#xD;
             (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral&#xD;
             oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago.&#xD;
             In the case of oophorectomy alone, only when the reproductive status of the woman has&#xD;
             been confirmed by follow up hormone level assessment is she considered not of child&#xD;
             bearing potential.&#xD;
&#xD;
         17. Current use of food or drugs known to be potent CYP3A4 inhibitors, drugs known to be&#xD;
             potent CYP3A4 inducers, and drugs that are known to prolong the QT interval unless the&#xD;
             prohibited concomitant medication can be replaced by other drugs of less potential to&#xD;
             inhibit or induce CYP3A4 or prolong QT interval (See Appendix C for Prohibited&#xD;
             Concomitant Medications).&#xD;
&#xD;
         18. Patients whose tumors contain both low-grade serous carcinoma (LGSC) and high-grade&#xD;
             serous carcinoma (HGSC)&#xD;
&#xD;
         19. Patients with history of haemopoietic stem cell or bone marrow transplant.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Slomovitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>GOG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Klein, MEd</last_name>
    <phone>215-854-0770</phone>
    <email>jklein@gog.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia Calderon</last_name>
      <email>Emilia.Calderon@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Lee-may Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Heath</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Lynn</last_name>
      <email>melissa.lynn@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Merry Markham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Rokakis</last_name>
      <email>Eleni.Rokakis@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hye Sook Chon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cuvo</last_name>
      <phone>404-236-8304</phone>
      <email>jennifer.cuvo@northside.com</email>
    </contact>
    <investigator>
      <last_name>Meaghan Tenney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Flanagan</last_name>
      <phone>847-570-1768</phone>
      <email>tflanagan@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Mary Tilley Jenkins-Vogel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Care Center, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Cruz</last_name>
      <email>cynthia.cruzrivera@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Michael Callahan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital Cancer Care Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Velfling</last_name>
      <phone>734-712-4950</phone>
      <email>Christina.Velfling@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>J. Rebecca Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janelle Johnson</last_name>
      <email>Johnson.Janelle1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Saravut (John) Weroha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>05055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelin Kihwele</last_name>
      <email>Jacqueline.M.Kihwele@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Evelyn Fleming, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aretha DiSalvo</last_name>
      <email>Aretha.disalvo@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Donna McNamara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital Inc.</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasey Bessada, BSN, RN</last_name>
      <email>mailto:kbessad@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Eleanora Teplinisky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance/University of New Mexico Comprehensive Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Westgate</last_name>
      <email>swestgate@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Carolyn Muller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest Gynecologic Oncology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Westgate</last_name>
      <email>swestgate@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Carolyn Muller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Willey</last_name>
      <email>lmwilley@premierhealth.com</email>
    </contact>
    <investigator>
      <last_name>Michael Guy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Myers</last_name>
      <email>molly.myers@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Floor Backes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HeeSun Kim</last_name>
      <email>HeeSun-Kim@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Holman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Care Specialists and Research Institute , LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Powell</last_name>
      <email>melissa.powell@ocsri.org</email>
    </contact>
    <investigator>
      <last_name>Eric Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital/West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Makarevich,</last_name>
      <email>hannah.makarevich@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Krivak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilynn Powell</last_name>
      <email>Marilyn.Powell@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Shahin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Dionne</last_name>
      <email>mdionne@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Katina Robison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkland Health and Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Paulsen</last_name>
      <email>annette.paulsen@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Paulsen</last_name>
      <email>annette.paulsen@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty Woodall</last_name>
      <email>mwoodall@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Shannon Westin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Texas Medical Center - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Robazetti</last_name>
      <email>sonia.c.robazetti@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Lucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Willowbrook Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaya Kamath</last_name>
      <email>jskamath@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Aparna KAmat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaya Kamat</last_name>
      <email>jskamath@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Aparna Kamath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Sugar Land Hospital</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaya Kamath</last_name>
      <email>jskamath@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Aparna Kamat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovary</keyword>
  <keyword>peritoneum</keyword>
  <keyword>fallopian tube</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

